FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601864634> ?p ?o ?g. }

• W2601864634 abstract "4072 Background: S-1, a novel oral fluoropyrimidine, plus cisplatin (SP) regimen is one of the standard chemotherapy as first-line for advanced gastric cancer. ToGA study demonstrated that trastuzumab (T-mab) combination regimen improved the overall survival of patients with HER2-positive advanced gastric cancer. However, there was no study evaluating the efficacy and the safety of T-mab in combination with S-1 plus cisplatin (SP) regimen. Therefore, we planned this study to examine the efficacy and the safety of the SP plus T-mab. Methods: Patients confirmed to be HER2-positive by IHC and/or FISH (IHC 3+ or IHC 2+ and FISH positive) received S-1 at 80 mg/m 2 po, day 1-14, and cisplatin 60 mg/m 2 iv, day 1 plus trastuzumab 8 mg/kg iv, day 1 (6 mg/kg iv, d1 from 2nd course), repeated every 3 weeks until disease progression. Primary endpoint was response rate (RR). Secondary endpoints were progression-free survival, overall survival and safety. The threshold response rate was defined as 35%, and the expected rate was set at 50% with a 80% power and a 1-sided alpha value of 0.1 and the calculated sample size was 50 patients. Results: A total of 56 patients (median age 66) were enrolled in this study. The efficacy and the safety analyses were conducted in the full analysis set of 53 patients. (Two patients were excluded for ineligibility and one was for no treatment). The confirmed RR assessed by the independent review committee was 67.9% (95% CI: 53.7 – 80.1), and the disease control rate was 94.3%. The median PFS was 7.1 months (95% CI: 6.0 – 10.1). The median OS was not reached. (The median follow-up time: 9.2 months) The main grade 3/4 adverse events were as follows: neutropenia 34%, leucopenia 8%, anorexia 23%, diarrhea 8%, hypoalbuminemia 4%, vomiting 6%, and increased creatinine 6%. Conclusions: This tri-week regimen with SP plus T-mab showed promising results in patients with HER2-positive advanced gastric cancer. Clinical trial information: UMIN000005739." @default.
• W2601864634 created "2017-04-07" @default.
• W2601864634 creator A5003882682 @default.
• W2601864634 creator A5005202372 @default.
• W2601864634 creator A5011235559 @default.
• W2601864634 creator A5020985742 @default.
• W2601864634 creator A5029101744 @default.
• W2601864634 creator A5040676201 @default.
• W2601864634 creator A5042824097 @default.
• W2601864634 creator A5043504350 @default.
• W2601864634 creator A5048919337 @default.
• W2601864634 creator A5054182211 @default.
• W2601864634 creator A5057163448 @default.
• W2601864634 creator A5060160999 @default.
• W2601864634 creator A5065342574 @default.
• W2601864634 creator A5070941567 @default.
• W2601864634 creator A5076533221 @default.
• W2601864634 date "2013-05-20" @default.
• W2601864634 modified "2023-10-03" @default.
• W2601864634 title "A phase ll study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1)." @default.
• W2601864634 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.4072" @default.
• W2601864634 hasPublicationYear "2013" @default.
• W2601864634 type Work @default.
• W2601864634 sameAs 2601864634 @default.
• W2601864634 citedByCount "0" @default.
• W2601864634 crossrefType "journal-article" @default.
• W2601864634 hasAuthorship W2601864634A5003882682 @default.
• W2601864634 hasAuthorship W2601864634A5005202372 @default.
• W2601864634 hasAuthorship W2601864634A5011235559 @default.
• W2601864634 hasAuthorship W2601864634A5020985742 @default.
• W2601864634 hasAuthorship W2601864634A5029101744 @default.
• W2601864634 hasAuthorship W2601864634A5040676201 @default.
• W2601864634 hasAuthorship W2601864634A5042824097 @default.
• W2601864634 hasAuthorship W2601864634A5043504350 @default.
• W2601864634 hasAuthorship W2601864634A5048919337 @default.
• W2601864634 hasAuthorship W2601864634A5054182211 @default.
• W2601864634 hasAuthorship W2601864634A5057163448 @default.
• W2601864634 hasAuthorship W2601864634A5060160999 @default.
• W2601864634 hasAuthorship W2601864634A5065342574 @default.
• W2601864634 hasAuthorship W2601864634A5070941567 @default.
• W2601864634 hasAuthorship W2601864634A5076533221 @default.
• W2601864634 hasConcept C121608353 @default.
• W2601864634 hasConcept C126322002 @default.
• W2601864634 hasConcept C143998085 @default.
• W2601864634 hasConcept C2779786085 @default.
• W2601864634 hasConcept C2781413609 @default.
• W2601864634 hasConcept C530470458 @default.
• W2601864634 hasConcept C71924100 @default.
• W2601864634 hasConceptScore W2601864634C121608353 @default.
• W2601864634 hasConceptScore W2601864634C126322002 @default.
• W2601864634 hasConceptScore W2601864634C143998085 @default.
• W2601864634 hasConceptScore W2601864634C2779786085 @default.
• W2601864634 hasConceptScore W2601864634C2781413609 @default.
• W2601864634 hasConceptScore W2601864634C530470458 @default.
• W2601864634 hasConceptScore W2601864634C71924100 @default.
• W2601864634 hasLocation W26018646341 @default.
• W2601864634 hasOpenAccess W2601864634 @default.
• W2601864634 hasPrimaryLocation W26018646341 @default.
• W2601864634 isParatext "false" @default.
• W2601864634 isRetracted "false" @default.
• W2601864634 magId "2601864634" @default.
• W2601864634 workType "article" @default.